<DOC>
	<DOCNO>NCT00334126</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( effectiveness drug ) safety antipsychotic paliperidone ER compare another antipsychotic , quetiapine , placebo patient acutely ill symptom schizophrenia .</brief_summary>
	<brief_title>Evaluation Effectiveness Safety Paliperidone ER ( Extended-release ) Compared With Quetiapine Patients With Schizophrenia</brief_title>
	<detailed_description>This randomize ( patient assign different treatment base chance ) , double blind ( neither patient physician know whether drug placebo take , dosage ) , placebo control , parallel group study compare efficacy safety paliperidone ER quetiapine treatment patient schizophrenia acutely ill . The duration study 42 day . During first phase ( Day 0 - Day 14 ) patient receive increase dos treatment assign ( start 3mg increase 9 mg 12 mg paliperidone ER ; start 50 mg increase 600 mg 800 mg quetiapine ; number capsule placebo ) . During second phase ( Day 15 - Day 42 ) , patient continue take dose medication receive day 14 , may also receive medication investigator determines need treat ongoing symptom . The hypothesis study paliperidone ER good quetiapine short term treat acutely ill patient schizophrenia . Primary outcome change total score PANSS ( Positive Negative Syndrome scale Schizophrenia ) first phase study ( Day 0 - Day 14 ) . Secondary outcome include time response , time readiness discharge , additional medication use second phase study ( Day 15- Day 42 ) patient receive paliperidone ER compare quetiapine . Safety paliperidone ER compare quetiapine throughout study ( Day 0 - Day 42 ) base report adverse event , result laboratory test ( hematology , biochemistry , urinalysis ) , vital sign ( blood pressure , pulse , weight ) , electrocardiogram , movement disorder scale ( Abnormal Involuntary Movement Scale , Barnes Akathisia Scale , Simpson-Angus Rating Scale ) . Patients may participate pharmacogenomic ( DNA ) analysis , choose . Patients receive study drug mouth total 42 day . Study medication increase maximum tolerated dos Paliperidone ER 9mg 12mg/day Quetiapine 600mg 800mg day 8 . From day 15 day 42 ( end study ) patient eligible additional psychotropic medication investigator ' discretion .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Diagnostic Statistical Manual Fourth Edition ( DSMIV ) diagnosis schizophrenia ( paranoid , disorganize undifferentiated type ) score &gt; =4 least two subset select PANSS item total score five item &gt; =17 score &gt; =5 CGIS ( clinical global impression severity ) body weight least 60kg willing hospitalize 9 day initially A primary active mental illness diagnosis schizophrenia subject whose psychotic symptom explain substance intake medical illness pregnancy , breastfeeding , plan become pregnant history treatment resistance ( defined failure respond 2 adequate trial different antipsychotic medication clozapine give adequate dose sufficient time ) unstable significant medical illness would increase risk take study medication would confuse interpretation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>paliperidone</keyword>
	<keyword>quetiapine</keyword>
	<keyword>Seroquel</keyword>
	<keyword>placebo</keyword>
</DOC>